WHAT IS CLAIMED IS:

1. An anhydrous crystalline hemi-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the salt exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from the group consisting of 8.2, 8.6, 9.1, and 9.5 degrees 2θ±0.3 degrees 2θ.

2. The compound of claim 1, wherein the crystalline tianeptine hemi-oxalate salt exhibits an XRPD pattern further comprising at least one ~~additional~~ peak selected from the group consisting of 4.5, 11.5, 14.2, 15.2, 15.8, 16.4, 19.2, 22.1, 23.9, 26.9, and 27.4 degrees 2θ±0.3 degrees 2θ.

~~3. An anhydrous crystalline mono-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the salt exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from the group consisting of 10.1 and 10.5 degrees 2θ±0.3 degrees 2θ.~~

~~4. The compound of claim 3, wherein the crystalline tianeptine mono-oxalate salt exhibits an XRPD pattern comprising at least one additional peak selected from the group consisting of 7.5, 8.3, 11.9, 14.7, 16.2, 16.3, 17.9, 18.7, 21.0, 21.7, and 22.1 degrees 2θ±0.3 degrees 2θ.~~

~~5. A mixture of an anhydrous hemi-oxalate salt and an anhydrous crystalline mono-oxalate salt of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine), wherein the mixture exhibits an XRPD pattern comprising at least one peak selected from the group consisting of 10.2 and 10.5 degrees 2θ±0.3 degrees 2θ.~~

~~6. The mixture of claim 5, wherein the mixture exhibits an XRPD pattern further comprising at least one additional peak selected from the group consisting of 7.5, 8.3, 11.9, 14.7, 16.2, 16.3, 17.9, 18.7, 21.0, 21.7, and 22.1 degrees 2θ±0.3 degrees 2θ.~~

○○

3. The compound of claim 1, wherein the crystalline tianeptine hemi-oxalate salt exhibits an XRPD pattern comprising the peaks of 8.2, 8.6, 9.1, and 9.5 degrees 2θ±0.3 degrees 2θ.

4. A pharmaceutical composition comprising one or more salts of any one of claims 1-3 and a pharmaceutically acceptable carrier, diluent, or excipient.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in a solid form, a liquid from, a suspension form, a sustained release form, a delayed release form, or an extended release form.

○○